Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tessa Kennedy-Martin, Rosirene Paczkowski & Sharon Rayner. (2015) Utility values in diabetic kidney disease: a literature review. Current Medical Research and Opinion 31:7, pages 1271-1282.
Read now
Read now
Lisa Bernard, David Mendelssohn, Elizabeth Dunn, Colin Hutchison & Daniel T Grima. (2013) A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. Journal of Medical Economics 16:1, pages 1-9.
Read now
Read now
Articles from other publishers (29)
Jacie T. Cooper, Andrew Lloyd, Juan Jose Garcia Sanchez, Elisabeth Sörstadius, Andrew Briggs & Phil McFarlane. (2020) Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health and Quality of Life Outcomes 18:1.
Crossref
Crossref
Min‐Woo Jo, Hyeon‐Jeong Lee, Dong‐Ryeol Ryu, Jongha Park, Minsu Ock & Seon‐Ha Kim. (2020) Estimation of population‐based utility weights for health states of chronic kidney disease, dialysis and kidney transplantation. Nephrology 25:7, pages 544-550.
Crossref
Crossref
Callum FarisAlyssa HeiserOlivia QuatelaMatthew JacksonOren TesslerNate Jowett & Linda N. Lee. (2019) Health utility of rhinectomy, surgical nasal reconstruction, and prosthetic rehabilitation. The Laryngoscope 130:7, pages 1674-1679.
Crossref
Crossref
Käthe Goossen, Monika Becker, Mark R. Marshall, Stefanie Bühn, Jessica Breuing, Catherine A. Firanek, Simone Hess, Hisanori Nariai, James A. Sloand, Qiang Yao, Tae Ik Chang, JinBor Chen, Ramón Paniagua, Yuji Takatori, Jun Wada & Dawid Pieper. (2020) Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials. American Journal of Kidney Diseases 75:6, pages 830-846.
Crossref
Crossref
Angela Yee-Moon Wang, Junhui Zhao, Brian Bieber, Talerngsak Kanjanabuch, Martin Wilkie, Mark R Marshall, Hideki Kawanishi, Jeffrey Perl & Simon Davies. (2020) International comparison of peritoneal dialysis prescriptions from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 40:3, pages 310-319.
Crossref
Crossref
Mark R. Marshall, Chun-Yuan Hsiao, Philip K. Li, Masaaki Nakayama, S. Rabindranath, Rachael C. Walker, Xueqing Yu & Suetonia C. Palmer. (2019) Association of incident dialysis modality with mortality: a protocol for systematic review and meta-analysis of randomized controlled trials and cohort studies. Systematic Reviews 8:1.
Crossref
Crossref
Xuemei Li, Hong Xu, Nan Chen, Zhaohui Ni, Menghua Chen, Limeng Chen, Jie Dong, Wei Fang, Yusheng Yu, Xiao Yang, Jianghua Chen, Xueqing Yu, Qiang Yao, James A. Sloand & Mark R. Marshall. (2018) The Effect of Automated versus Continuous Ambulatory Peritoneal Dialysis on Mortality Risk in China. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 38:2_suppl, pages 25-35.
Crossref
Crossref
Callum Faris, Oren Tessler, Alyssa Heiser, Tessa Hadlock & Nate Jowett. (2018) Evaluation of Societal Health Utility of Facial Palsy and Facial Reanimation. JAMA Facial Plastic Surgery 20:6, pages 480-487.
Crossref
Crossref
Juan Jose Yepes-Nuñez, Yuan Zhang, Feng Xie, Pablo Alonso-Coello, Anna Selva, Holger Schünemann & Gordon Guyatt. (2017) Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences' studies. Journal of Clinical Epidemiology 85, pages 21-31.
Crossref
Crossref
Tracey Jones-Hughes, Tristan Snowsill, Marcela Haasova, Helen Coelho, Louise Crathorne, Chris Cooper, Ruben Mujica-Mota, Jaime Peters, Jo Varley-Campbell, Nicola Huxley, Jason Moore, Matt Allwood, Jenny Lowe, Chris Hyde, Martin Hoyle, Mary Bond & Rob Anderson. (2016) Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technology Assessment 20:62, pages 1-594.
Crossref
Crossref
Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Louise Crathorne, Chris Cooper, Jo Varley-Campbell, Ruben Mujica-Mota, Helen Coelho, Nicola Huxley, Jenny Lowe, Jan Dudley, Stephen Marks, Chris Hyde, Mary Bond & Rob Anderson. (2016) Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation. Health Technology Assessment 20:61, pages 1-324.
Crossref
Crossref
Mark R. Marshall, Kevan R. Polkinghorne, Peter G. Kerr, Carmel M. Hawley, John W.M. Agar & Stephen P. McDonald. (2016) Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations. American Journal of Kidney Diseases 67:4, pages 617-628.
Crossref
Crossref
Blanca Gros, Antonio Galán, Emilio González-Parra, Jose A Herrero, Maria Echave, Stefan Vegter, Keith Tolley & Itziar Oyagüez. (2015) Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. Health Economics Review 5:1.
Crossref
Crossref
Mark R. Marshall, Kevan R. Polkinghorne, Peter G. Kerr, John W.M. Agar, Carmel M. Hawley & Stephen P. McDonald. (2015) Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. American Journal of Kidney Diseases 66:3, pages 489-498.
Crossref
Crossref
R. C. Walker, R. L. Morton, A. Tong, M. R. Marshall, S. Palmer & K. Howard. (2015) Patient and caregiver preferences for home dialysis--the home first study: a protocol for qualitative interviews and discrete choice experiments. BMJ Open 5:4, pages e007405-e007405.
Crossref
Crossref
Kirsten Howard, Phil A. McFarlane, Mark R. Marshall, Deborah O. Eastwood & Rachael L. Morton. (2015) Funding and planning: What you need to know for starting or expanding a home hemodialysis program. Hemodialysis International 19, pages S23-S42.
Crossref
Crossref
Mark R. Marshall, Rachael C. Walker, Kevan R. Polkinghorne & Kelvin L. Lynn. (2014) Survival on Home Dialysis in New Zealand. PLoS ONE 9:5, pages e96847.
Crossref
Crossref
Carlos Wong, In-wa Luk, Margaret Ip & Joyce H.S. You. (2014) Prevention of gram-positive infections in peritoneal dialysis patients in Hong Kong: A cost-effectiveness analysis. American Journal of Infection Control 42:4, pages 412-416.
Crossref
Crossref
Mangala Rajan, Kuan-Chi Lai, Chin-Lin Tseng, Shirley Qian, Alfredo Selim, Lewis Kazis, Leonard Pogach & Anushua Sinha. (2012) Estimating utilities for chronic kidney disease, using SF-36 and SF-12-based measures: challenges in a population of veterans with diabetes. Quality of Life Research 22:1, pages 53-64.
Crossref
Crossref
Charles Christian Adarkwah, Afschin Gandjour, Maren Akkerman & Silvia Evers. (2013) To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease - a Dutch Perspective. Kidney and Blood Pressure Research 37:2-3, pages 168-180.
Crossref
Crossref
Fredric O. Finkelstein, Kelli L. Arsenault, Ana Taveras, Kwabena Awuah & Susan H. Finkelstein. (2012) Assessing and improving the health-related quality of life of patients with ESRD. Nature Reviews Nephrology 8:12, pages 718-724.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
105
125
.
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
293
304
.
Charles Christian Adarkwah, Afschin Gandjour, Maren Akkerman & Silvia M. Evers. (2011) Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model. PLoS ONE 6:10, pages e26139.
Crossref
Crossref
Stefan Vegter, Keith Tolley, Michael S. Keith & Maarten J. Postma. (2011) Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Chronic Kidney Disease Before and During Dialysis. Value in Health 14:6, pages 852-858.
Crossref
Crossref
Reiko Tajima, Masahide Kondo, Hirayasu Kai, Chie Saito, Masafumi Okada, Hideto Takahashi, Mariko Doi, Shuichi Tsuruoka & Kunihiro Yamagata. (2010) Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clinical and Experimental Nephrology 14:4, pages 340-348.
Crossref
Crossref
Stefan Vegter, Annalisa Perna, Wâtse Hiddema, Piero Ruggenenti, Giuseppe Remuzzi, Gerjan Navis & Maarten J. Postma. (2009) Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenetics and Genomics 19:9, pages 695-703.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Organ Transplantation 14:2, pages 211-217.
Crossref
Crossref
Javier Soto Álvarez. (2013) Cambios en el valor de la utilidad dependiendo del método empleado en su medición y del país y cultura donde se haya obtenido: ¿cómo pueden afectar a los resultados de los análisis coste-utilidad?. PharmacoEconomics Spanish Research Articles 5:2, pages 67-70.
Crossref
Crossref